None listed
Conditions
Brief summary
The proposed study investigates zinc's impact on lung function, IPF-related complications including pulmonary hypertension, and acute exacerbation in IPF. The findings will establish a rationale for incorporating zinc into IPF management and lay the foundation for further research into zinc status monitoring in existing IPF care protocols.
Interventions
Zinc gluconate, 30 mg will be administered as a daily oral tablet for 12 months. Adherence will be monitored through tablet returns, where participants will be given a bottle each month, and the remaining pills will be counted at each visit to assess compliance with the treatment regimen.
Sponsors
University of Adelaide
Study design
Allocation
Randomised controlled trial
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Patients 40 years of age or older who have received a diagnosis of IPF according to 2022 international guidelines and confirmed by a multidisciplinary team.
Exclusion criteria
IPF patients with severe co-existing medical conditions as determined by the investigators such as but not limited to advanced cardiovascular diseases, uncontrolled diabetes, or malignancies.
Outcome results
None listed